Clinical Trial Update: Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of irofulven for metastatic or recurrent colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irofulven (irofulven)

Snippet

Sponsor: University of Chicago | Conditions: Colorectal Cancer | Phase 2 | Status: WITHDRAWN